Working… Menu

Alcohol, Inflammation, and Mindfulness Study (AIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02994043
Recruitment Status : Recruiting
First Posted : December 15, 2016
Last Update Posted : July 12, 2019
Information provided by (Responsible Party):
Kent Hutchison, University of Colorado, Boulder

Brief Summary:
The goal of the AIM Study is to examine the effectiveness of Mindfulness Based Relapse Prevention (MBRP) versus Relapse Prevention (RP) for the treatment of Alcohol Use Disorders (AUD) by implementing an 8-week long intervention and examining neurobiological, immunological, and epigenetic characteristics of AUD.

Condition or disease Intervention/treatment Phase
Alcohol Use Disorder Behavioral: Mindfulness Plus Relapse Prevention Therapy Behavioral: Relapse Prevention Therapy Not Applicable

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 226 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of Action.
Actual Study Start Date : November 9, 2016
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : February 28, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: MBRP Behavioral: Mindfulness Plus Relapse Prevention Therapy
An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.

Active Comparator: RP Behavioral: Relapse Prevention Therapy
An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.

Primary Outcome Measures :
  1. Reduction of heavy drinking days [ Time Frame: 4, 8, 20, and 32 weeks ]
    Timeline Follow-back measure of heavy drinking days in the last month (4+ for women, 5+ for men)

  2. Decrease in methylation of key genes involved in Alcohol Use Disorders [ Time Frame: 4, 8, 20, and 32 weeks ]
    Methylation on immune-linked genes.

  3. Decrease in inflammation biomarkers [ Time Frame: 4, 8, 20, and 32 weeks ]
    Inflammatory cytokines.

  4. Changes in Left and Right Executive Control Network (LECN and RECN) connectivity detected by MRI [ Time Frame: 8 weeks ]
    Connectivity related to cognitive control.

  5. Changes in blood-oxygen level dependent (BOLD) activation detected by MR [ Time Frame: 8 weeks ]
    BOLD related to craving.

Secondary Outcome Measures :
  1. Changes in gut microbiota populations [ Time Frame: 8 Weeks ]
    Gut microbiota diversity and composition.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. Have a primary Diagnostic Statistical Manual-V (DSM-V) diagnosis of alcohol use disorder;
  2. Must be within 10 days of last drink;
  3. Must have been drinking heavily (criteria dependent upon individual?s age, gender, and BMI) for a consistent period of time;
  4. Must have a breath alcohol level of 0 at screening;
  5. Must have a Clinical Institute Withdrawal Assessment (CIWA) score less than 8 (indicating no need for medical detox);
  6. Must have expressed a desire during their initial screen to reduce the number of drinks they regularly consume

Exclusion Criteria:

  1. Currently taking any medications for the treatment of psychiatric disorders, including substance use disorders, mood disorders, and psychosis;
  2. Pregnant, as indicated by a pregnancy test which will be administered at baseline;
  3. Positive for, sedatives, opiates, cocaine, or amphetamine on drug screen at baseline;
  4. Meets criteria for psychotic disorder, bipolar disorder, or a major depressive episode

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02994043

Layout table for location contacts
Contact: Alexandra Zabelski
Contact: Hollis Karoly

Layout table for location information
United States, Colorado
University of Colorado Boulder Recruiting
Boulder, Colorado, United States, 80301
Contact: Suzanne Taborsky-Barba         
Sponsors and Collaborators
University of Colorado, Boulder

Layout table for additonal information
Responsible Party: Kent Hutchison, Professor, University of Colorado, Boulder Identifier: NCT02994043     History of Changes
Other Study ID Numbers: 16-0056
First Posted: December 15, 2016    Key Record Dates
Last Update Posted: July 12, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders